9/9/2010

Rhythm Pharmaceuticals has raised $40 million in a Series A funding round. The Boston-based startup is expected to use the proceeds to fund the clinical trials of its experimental peptide-based drugs, including RM-493, its drug candidate for diabetes and obesity.

Related Summaries